1 Lilly also reduced the price of the 2.5 mg and 5 mg vials. These new offerings are ... receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...